The Democratic Republic of Congo just received a shipment of 16,250 doses of the Ervebo vaccine, a critical tool in battling one of the country's deadliest Ebola outbreaks. The doses landed in Kinshasa, marking the first installment of 70,000 pledged by the World Health Organization (WHO) and its partners.
Here’s the catch: Ervebo is approved for the Zaire strain of Ebola. The current outbreak? It’s the Bundibugyo strain. Which, if you're keeping score, does not yet have an approved vaccine or treatment. Because apparently that's where we are now.
A Clinical Trial in Real-Time
Good news, though: early animal trials suggest Ervebo might offer some protection against the Bundibugyo strain. So, while the situation is undeniably serious – with the virus having claimed over 2,500 lives from nearly 5,300 confirmed cases – there's a glimmer of scientific hope.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxDRC's health minister, Samuel Roger Kamba, pointed out that Ervebo isn't new to the region; it was used "on a very large scale" during the 2018-2020 outbreak. This time around, 20,000 of the new doses will be dedicated to a clinical trial, specifically testing Ervebo’s effectiveness against the Bundibugyo variant. The rest will go to the front lines, protecting the health workers who are, quite literally, putting their lives on the line.
This outbreak, declared in mid-May but likely simmering for weeks prior, is proving particularly stubborn. The UN has warned that infections are spreading "exponentially," and experts from the Africa Centres for Disease Control and Prevention suggest transmission hasn't even peaked yet – it could triple. Armed conflict, slow case identification, and dodgy infrastructure in eastern DRC are all conspiring to make an already dire situation even more complicated. Because when it rains, it pours.
